WO2004055032A1 - Adenosine derivative in polymorph v form - Google Patents

Adenosine derivative in polymorph v form Download PDF

Info

Publication number
WO2004055032A1
WO2004055032A1 PCT/EP2003/014508 EP0314508W WO2004055032A1 WO 2004055032 A1 WO2004055032 A1 WO 2004055032A1 EP 0314508 W EP0314508 W EP 0314508W WO 2004055032 A1 WO2004055032 A1 WO 2004055032A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphic form
chloro
oxadiazol
tert
butyl
Prior art date
Application number
PCT/EP2003/014508
Other languages
French (fr)
Inventor
Richard Freer
John Charles Roberts
Mark Ralph Shipton
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to AU2003298204A priority Critical patent/AU2003298204A1/en
Publication of WO2004055032A1 publication Critical patent/WO2004055032A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to heterocyclyl substituted adenosine derivatives. More particularly the invention is concerned with particular physical forms of (2S,3S,4R,5R)-2-(5- tert-butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]- tetrahydrofuran-3,4-diol, pharmaceutical formulations thereof and their use in therapy.
  • (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)- purin-9-yl]-tetrahydrofuran-3,4-diol has activity at the adenosine A1 receptor.
  • WO99/67262 (Glaxo Group Limited) discloses certain heterocyclyl adenosine derivatives including (2S l 3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2- fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol, Example 14 of WO99/67262, the structure of which is indicated below as the compound of formula (A):
  • the preparation of the compound of formula (A) is described in WO99/67262.
  • the compound of formula (A) may be prepared by the reaction of 4-chloro-2-fluoroaniline with an appropriate purinyl derivative having a suitable leaving group in the 6-position of the purine ring, optionally in the presence of a solvent at elevated temperatures.
  • the compound of formula (A) may be prepared by treating 9- ⁇ (3aR,4R,6S,6aR)-6-[5-tert- butyl-1 ,3,4-oxadiazol-2-yl]-2,2-dimethyltetrahydrofuro[3,4-d][1 ,3]dioxol-4-yl ⁇ -N-(4-chloro-2- fluorophenyl)-9H-purin-6-amine with trifluoroacetic acid followed by treatment with sodium bicarbonate. Extraction of the product into ethyl acetate followed by evaporation in vacuo provides the compound of formula (A) as a buff solid.
  • Polymorph V is particularly suitable for bulk preparation and handling and thus may be useful in the preparation of pharmaceutical formulations.
  • Polymorph V may be useful in the preparation of pharmaceutical formulations.
  • the invention provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]- oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph V as herein defined.
  • (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)- purin-9-yl]-tetrahydrofuran-3,4-diol may be prepared in polymorphic form V by crystallisation of the compound under suitable conditions.
  • Polymorph V may be prepared substantially free from alternative polymorphs by controlling crystallisation conditions.
  • the invention provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2- yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph V as herein defined substantially free of any other polymorph.
  • the invention provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2- yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph V as herein defined substantially free of impurities.
  • substantially free is meant containing less than 10%, preferably less than 5%, more preferably less than 2%, of alternative polymorph or impurity.
  • (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2- fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph V may be obtained by treating 9- ⁇ (3aR,4R,6S,6aR)-6-[5-(tert-butyl)-1 ,3,4-oxadiazol-2-yl]-2,2- dimethyltetrahydrofuro[3,4-d][1 ,3]dioxol-4-yl)-N-(4-chloro-2-fluorophenyl)-9H-purin-6-amine (less than 98% pure, preferably 96-98% pure) with trifluoroacetic acid/water followed by neutralisation with aqueous ammonium hydroxide in the presence of m
  • Figure I shows X-Ray diffraction data obtained for Polymorph V.
  • Figure II shows a Raman spectrum of Polymorph V.
  • Figure III shows an infrared spectrum of Polymorph V.
  • Polymorph V has been characterised by X-ray powder diffraction (XRPD) studies , Raman spectroscopy and infrared spectroscopy.
  • Polymorph V is characterised by having signals in its Infrared spectra substantially at 3432, 3427, 3423, 3419, 860 and 856 cm-1.
  • Polymorph V is characterised by having peaks in its Raman spectra substantially at 3420,1616, 1586 and 1294 cm-1.
  • Polymorph V is characterised by having an XRPD pattern with signals substantially at 5.42, 7.99, 8.89, 9.66, 10.34 10.89, 11.84 and 12.37 (degrees 2-theta).
  • XRPD peak positions are affected by differences in sample height.
  • the peak positions quoted herein are thus subject to a variation of +/- 0.15 degrees 2-theta.
  • the present invention also provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]oxadiazol-2-yl)-5- [6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol characterised in that it: i) provides an XRPD spectrum substantially as illustrated in Figure I; and/or ii) provides a Raman spectrum substantially as illustrated in Figure II; and/or iii) provides an infrared spectrum substantially as illustrated in Figure III.
  • the present invention further provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]oxadiazol-2-yl)-
  • This invention further provides for a pharmaceutical composition
  • a pharmaceutical composition comprising (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)- purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V, and a pharmaceutically acceptable carrier and/or excipient.
  • Suitable pharmaceutically acceptable carriers and excipients are described in WO 99/67262.
  • (2S,3S,4R,5R)-2-(5-tert-Butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)- purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V may be used for decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain (for example inflammatory pain and neuropathic pain), migraine, CNS disorder, or sleep apnoea, as described in WO 99/67262.
  • the present invention therefore provides (2S,3S,4R ) 5R)-2-(5-tert-butyl- [1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4- diol in polymorphic form V for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, migraine, CNS disorder, or sleep apnoea.
  • (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)- purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V may be used in the manufacture of a medicament for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain (for example inflammatory pain and neuropathic pain), migraine, CNS disorder, or sleep apnoea, as described in WO 99/67262.
  • the present invention provides the use of (2S,3S,4R,5R)-2-(5-tert- butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]- tetrahydrofuran-3,4-diol in polymorphic form V in the manufacture of a medicament for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain (for example inflammatory pain and neuropathic pain), migraine, CNS disorder, or sleep apnoea.
  • the present invention also provides a method of treating a patient suffering from a condition where there is an advantage in decreasing plasma free fatty acid concentration; or reducing heart rate; or treating a patient suffering from ischemic heart disease, peripheral vascular disease, stroke, pain (for example inflammatory pain and neuropathic pain), migraine, CNS disorder, or sleep apnoea comprising administering a therapeutically effective amount of of (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2- yl)-5-[6-(4-chloro-2-fluorophenylamino)-puhn-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V.
  • WO 99/67262 (Glaxo Group Limited) is incorporated by reference herein as though fully set forth.
  • reaction mixture was neutralised by careful addition to 5M aqueous NH 4 OH in the presence of methanol, maintaining a temperature of 20-25°C.
  • the mixture was then cooled to 5°C to complete precipitation of the product, (2S,3S,4R,5R)-2-(5-tert- butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]- tetrahydrofuran-3,4-diol.
  • the solid is then filtered off, washed with aqueous methanol, stirred in water and dried in vacuo at 40-50°C.
  • the sample preparation and acquisition conditions were as follows:
  • Samples were lightly ground and packed (top-filling) into sample cups. Instrumentation consisted of a Bruker D8 Advance X-Ray powder diffractometer configured with a Cu anode (40 kV 40 mA), variable divergence slit, primary and secondary Soller slits, and a position sensitive detector. Data were acquired over the range 2 - 35 degrees 2-theta using a step size of 0.0145 degrees 2-theta (time per step: 1 s). Samples were rotated.
  • Raman spectra were acquired using a Nicolet 960 ESP FT-Raman spectrometer. Samples were held in glass vials; spectra of 5 different points on a sample were averaged. Data collection parameters include: Laser power: 400 mW, Resolution: 4 cm- 1 , Sample gain: 1.0, Detector: InGaAs, Beamsplitter: CaF2, Correction: none, Zero filling: none, Apodization: Happ-Genzel, Phase correction: Power spectrum.
  • Infrared Spectroscopy Infrared Spectroscopy Infrared spectra of the samples were obtained as Nujol mulls using a Perkin-Elmer 2000 FT-IR spectrometer. Spectra were recorded by averaging 2 scans and using a resolution of 2cm-1 , scan interval of 0.5cm-1 and a spectral range of 4000-450cm-1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

(2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V.

Description

POLYMORPH
The present invention relates to heterocyclyl substituted adenosine derivatives. More particularly the invention is concerned with particular physical forms of (2S,3S,4R,5R)-2-(5- tert-butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]- tetrahydrofuran-3,4-diol, pharmaceutical formulations thereof and their use in therapy.
(2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)- purin-9-yl]-tetrahydrofuran-3,4-diol has activity at the adenosine A1 receptor.
WO99/67262 (Glaxo Group Limited) discloses certain heterocyclyl adenosine derivatives including (2Sl3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2- fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol, Example 14 of WO99/67262, the structure of which is indicated below as the compound of formula (A):
Figure imgf000002_0001
(A) The preparation of the compound of formula (A) is described in WO99/67262. The compound of formula (A) may be prepared by the reaction of 4-chloro-2-fluoroaniline with an appropriate purinyl derivative having a suitable leaving group in the 6-position of the purine ring, optionally in the presence of a solvent at elevated temperatures. Alternatively the compound of formula (A) may be prepared by treating 9-{(3aR,4R,6S,6aR)-6-[5-tert- butyl-1 ,3,4-oxadiazol-2-yl]-2,2-dimethyltetrahydrofuro[3,4-d][1 ,3]dioxol-4-yl}-N-(4-chloro-2- fluorophenyl)-9H-purin-6-amine with trifluoroacetic acid followed by treatment with sodium bicarbonate. Extraction of the product into ethyl acetate followed by evaporation in vacuo provides the compound of formula (A) as a buff solid.
We have now surprisingly found that the compound of formula (A) can be obtained in polymorphic forms. We have further found that the compound of formula (A) may be obtained by crystallisation under certain conditions in the form of polymorphic form V (hereinafter Polymorph V). There is thus provided as a first aspect of the invention (2S,3S,4R,5R)-2-(5-tert-butyl- [1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4- diol as polymorphic form V.
Polymorph V is particularly suitable for bulk preparation and handling and thus may be useful in the preparation of pharmaceutical formulations.
Polymorph V may be useful in the preparation of pharmaceutical formulations.
In a preferred aspect the invention provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]- oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph V as herein defined.
(2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)- purin-9-yl]-tetrahydrofuran-3,4-diol may be prepared in polymorphic form V by crystallisation of the compound under suitable conditions.
Polymorph V may be prepared substantially free from alternative polymorphs by controlling crystallisation conditions.
In a further aspect the invention provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2- yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph V as herein defined substantially free of any other polymorph.
In a further aspect the invention provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2- yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph V as herein defined substantially free of impurities.
By "substantially free" is meant containing less than 10%, preferably less than 5%, more preferably less than 2%, of alternative polymorph or impurity.
In general, (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2- fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph V may be obtained by treating 9-{(3aR,4R,6S,6aR)-6-[5-(tert-butyl)-1 ,3,4-oxadiazol-2-yl]-2,2- dimethyltetrahydrofuro[3,4-d][1 ,3]dioxol-4-yl)-N-(4-chloro-2-fluorophenyl)-9H-purin-6-amine (less than 98% pure, preferably 96-98% pure) with trifluoroacetic acid/water followed by neutralisation with aqueous ammonium hydroxide in the presence of methanol, maintaining a temperature of less than 25°C , preferably 20-25°C.
Interconversion of polymorph V to other polymorphs can occur under certain circumstances. The methods for the preparation of Polymorph V described herein constitute a further aspect of the present invention.
Description of Figures:
Figure I shows X-Ray diffraction data obtained for Polymorph V. Figure II shows a Raman spectrum of Polymorph V. Figure III shows an infrared spectrum of Polymorph V.
Polymorph V has been characterised by X-ray powder diffraction (XRPD) studies , Raman spectroscopy and infrared spectroscopy.
Polymorph V is characterised by having signals in its Infrared spectra substantially at 3432, 3427, 3423, 3419, 860 and 856 cm-1.
Infrared peaks are quoted to the nearest cm-1.
Polymorph V is characterised by having peaks in its Raman spectra substantially at 3420,1616, 1586 and 1294 cm-1.
Raman peaks are quoted to the nearest cm-1.
Polymorph V is characterised by having an XRPD pattern with signals substantially at 5.42, 7.99, 8.89, 9.66, 10.34 10.89, 11.84 and 12.37 (degrees 2-theta).
The skilled person will recognise that XRPD peak positions are affected by differences in sample height. The peak positions quoted herein are thus subject to a variation of +/- 0.15 degrees 2-theta.
It will be recognised that spectra and diffraction data will vary slightly according to various factors such as the temperature, concentration and instrumentation used. In order to account for this variability, signals and peak positions are quoted herein as being "substantially" at specific values.
The present invention also provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]oxadiazol-2-yl)-5- [6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol characterised in that it: i) provides an XRPD spectrum substantially as illustrated in Figure I; and/or ii) provides a Raman spectrum substantially as illustrated in Figure II; and/or iii) provides an infrared spectrum substantially as illustrated in Figure III. The present invention further provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]oxadiazol-2-yl)-
5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol characterised in that it: i) provides an XRPD spectrum with signals substantially at 5.42, 7.99, 8.89, 9.66,
10.34 10.89, 11.84 and 12.37 (degrees 2-theta); and/or ii) provides a Raman spectrum with signals substantially at 3420,1616, 1586 and
1294 cm-1 ; and/or iii) provides an infrared spectrum with signals substantially at 3432, 3427, 3423, 3418,
860 and 856 cm-1.
This invention further provides for a pharmaceutical composition comprising (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)- purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V, and a pharmaceutically acceptable carrier and/or excipient.
Suitable pharmaceutically acceptable carriers and excipients are described in WO 99/67262.
(2S,3S,4R,5R)-2-(5-tert-Butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)- purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V may be used for decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain (for example inflammatory pain and neuropathic pain), migraine, CNS disorder, or sleep apnoea, as described in WO 99/67262.
In a further aspect the present invention therefore provides (2S,3S,4R)5R)-2-(5-tert-butyl- [1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4- diol in polymorphic form V for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, migraine, CNS disorder, or sleep apnoea.
(2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)- purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V may be used in the manufacture of a medicament for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain (for example inflammatory pain and neuropathic pain), migraine, CNS disorder, or sleep apnoea, as described in WO 99/67262.
In a yet further aspect the present invention provides the use of (2S,3S,4R,5R)-2-(5-tert- butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]- tetrahydrofuran-3,4-diol in polymorphic form V in the manufacture of a medicament for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain (for example inflammatory pain and neuropathic pain), migraine, CNS disorder, or sleep apnoea.
In another aspect the present invention also provides a method of treating a patient suffering from a condition where there is an advantage in decreasing plasma free fatty acid concentration; or reducing heart rate; or treating a patient suffering from ischemic heart disease, peripheral vascular disease, stroke, pain (for example inflammatory pain and neuropathic pain), migraine, CNS disorder, or sleep apnoea comprising administering a therapeutically effective amount of of (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2- yl)-5-[6-(4-chloro-2-fluorophenylamino)-puhn-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V.
WO 99/67262 (Glaxo Group Limited) is incorporated by reference herein as though fully set forth.
The following examples illustrate the invention but are not intended as a limitation thereof.
EXAMPLES
9-{(3aR,4R,6S,6aR)-6-[5-(tert-butyl)-1 ,3,4-oxadiazol-2-yl]-2,2-dimethyltetrahydrofuro[3,4- d][1 ,3]dioxol-4-yl)-N-(4-chloro-2-fluorophenyl)-9H-purin-6-amine was prepared according to the methods described in WO99/67262, in particular intermediate 63.
Example 1 - Preparation of Polymorph V
9-{(3aR,4R,6S,6aR)-6-[5-(tert-butyl)-1 ,3,4-oxadiazol-2-yl]-2,2-dimethyltetrahydrofuro[3,4- d][1 ,3]dioxol-4-yl)-N-(4-chloro-2-fluorophenyl)-9H-purin-6-amine (purity 96.6%) was dissolved in 3.8 volumes of 9:1 v/v trifluoroacetic acid/water and the mixture stirred for 3 hours under ambient conditions, when the reaction is 95% complete by liquid chromatography. The reaction mixture was neutralised by careful addition to 5M aqueous NH4OH in the presence of methanol, maintaining a temperature of 20-25°C. The mixture was then cooled to 5°C to complete precipitation of the product, (2S,3S,4R,5R)-2-(5-tert- butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]- tetrahydrofuran-3,4-diol. The solid is then filtered off, washed with aqueous methanol, stirred in water and dried in vacuo at 40-50°C.
X-Ray Powder Diffraction
The sample preparation and acquisition conditions were as follows:
Samples were lightly ground and packed (top-filling) into sample cups. Instrumentation consisted of a Bruker D8 Advance X-Ray powder diffractometer configured with a Cu anode (40 kV 40 mA), variable divergence slit, primary and secondary Soller slits, and a position sensitive detector. Data were acquired over the range 2 - 35 degrees 2-theta using a step size of 0.0145 degrees 2-theta (time per step: 1 s). Samples were rotated.
Data obtained for Polymorph V are shown in Figure I.
Raman Spectroscopy
Raman spectra were acquired using a Nicolet 960 ESP FT-Raman spectrometer. Samples were held in glass vials; spectra of 5 different points on a sample were averaged. Data collection parameters include: Laser power: 400 mW, Resolution: 4 cm-1 , Sample gain: 1.0, Detector: InGaAs, Beamsplitter: CaF2, Correction: none, Zero filling: none, Apodization: Happ-Genzel, Phase correction: Power spectrum.
Raman spectra of Polymorph V is shown in Figure II.
Infrared Spectroscopy Infrared spectra of the samples were obtained as Nujol mulls using a Perkin-Elmer 2000 FT-IR spectrometer. Spectra were recorded by averaging 2 scans and using a resolution of 2cm-1 , scan interval of 0.5cm-1 and a spectral range of 4000-450cm-1.
An infrared spectrum of Polymorph V is shown in Figure

Claims

1. (2S,3S,4R,5R)-2-(5-tert-Butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2- fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V.
2. A pharmaceutical formulation comprising a polymorphic form V according to claim 1 , and a pharmaceutically acceptable carrier and/or excipient.
3. A polymorphic form according to claim 1 for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, migraine, CNS disorder, or sleep apnoea.
4. Use of a polymorphic form according to claim 1 in the manufacture of a medicament for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, migraine, CNS disorder, or sleep apnoea.
5. A method of treating a patient suffering from a condition where there is an advantage in decreasing plasma free fatty acid concentration; or reducing heart rate; or treating a patient suffering from ischemic heart disease, peripheral vascular disease, stroke, pain, migraine, CNS disorder, or sleep apnoea comprising administering a therapeutically effective amount of a polymorphic form according to claim 1.
6. (2S,3S,4R,5R)-2-(5-tert-butyl-[1 ,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2- fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V substantially as described herein in the specification and/or examples.
PCT/EP2003/014508 2002-12-18 2003-12-16 Adenosine derivative in polymorph v form WO2004055032A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003298204A AU2003298204A1 (en) 2002-12-18 2003-12-16 Adenosine derivative in polymorph v form

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43446402P 2002-12-18 2002-12-18
US60/434,464 2002-12-18

Publications (1)

Publication Number Publication Date
WO2004055032A1 true WO2004055032A1 (en) 2004-07-01

Family

ID=32595277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/014508 WO2004055032A1 (en) 2002-12-18 2003-12-16 Adenosine derivative in polymorph v form

Country Status (2)

Country Link
AU (1) AU2003298204A1 (en)
WO (1) WO2004055032A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067262A1 (en) * 1998-06-23 1999-12-29 Glaxo Group Limited Adenosine derivatives
WO2002074781A1 (en) * 2001-03-20 2002-09-26 Glaxo Group Limited Process for preparing n6-substituted aminopurine ribofuranose nucleosides
WO2003106475A2 (en) * 2002-06-17 2003-12-24 Glaxo Group Limited Process

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067262A1 (en) * 1998-06-23 1999-12-29 Glaxo Group Limited Adenosine derivatives
WO2002074781A1 (en) * 2001-03-20 2002-09-26 Glaxo Group Limited Process for preparing n6-substituted aminopurine ribofuranose nucleosides
WO2003106475A2 (en) * 2002-06-17 2003-12-24 Glaxo Group Limited Process

Also Published As

Publication number Publication date
AU2003298204A1 (en) 2004-07-09

Similar Documents

Publication Publication Date Title
US20230116935A1 (en) Rifaximin
US7384953B2 (en) Purification of rapamycin
EP3170833B1 (en) 20,23-piperidinyl-5-o-mycaminosyl-tylonolide polymorphs
EP1527082A2 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
HUT73418A (en) Process for preparing rapamycin carbonate esters and pharmaceutical compositions of immunosuppressive activity containing said compounds
CZ193995A3 (en) 2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)methoxy-1,3-propanediol derivative
WO2005105771A1 (en) Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
US20110224422A1 (en) Preparation of capecitabine
EP2855499A1 (en) Solid state forms of fidaxomycin and processes for preparation thereof
EP1534727B1 (en) Pharmaceutical compositions of crystalline beta-l-2'-deoxythymidine
SK13572002A3 (en) Crystalline form II of cabergoline, pharmaceutical composition and method for producing thereof
WO2019049174A1 (en) Solid state forms of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1h,3h)-dione hydrochloride and their processes for the preparation thereof
WO2004055032A1 (en) Adenosine derivative in polymorph v form
US20040162297A1 (en) Adenosine derivative in polymorph I form
CA2229718A1 (en) Process for the preparation of imidazolyl macrolide immunosuppressants
US20050222178A1 (en) Process
WO2004055034A1 (en) Polymorph
EP2128145A2 (en) Improved method for synthesizing lamotrigine
US20030176697A1 (en) Method for preparing crambescidin core acid intermediates and their use for preparing crambescidin alkaloid analogs as therapeutic agents
WO2004055033A1 (en) Adenosine derivative in polymorph iv form
EP2137202B1 (en) Process for the synthesis of ib-meca
US5777105A (en) Process for the preparation of imidazolyl macrolide immunosuppressants
US9120760B2 (en) Fluoro-homoneplanocin A and nucleoside derivatives, method for the synthesis thereof, and the pharmaceutical compositions comprising the same as an active component for treatment of cancer
KR0180566B1 (en) 2-amino-6-fluoro-9-(2-hydroxyethoxymethyl)pyurinester derivative
WO2020161742A1 (en) Novel crystalline polymorphs of sodium (4r,12as)-9-{[(2,4-difluorophenyl) methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2h-pyrido [1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate and process for preparation thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP